Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to ... ( Findings Presented At The American S...)

HOME >> MEDICINE >> TECHNOLOGY

Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)

Date:9/15/2008

Findings Presented At The American Society Of Clinical Psychopharmacology

Meeting

WELLESLEY HILLS, Mass., Sept. 15 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today that all oral drug delivery intellectual property will be sold at a sealed bid auction on October 10, 2008.

Topamax(R) produces adverse effects on cognitive functions at rates of over 40% in subjects with epilepsy. These effects manifest as confusion, psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech or language and word-finding difficulties. Using computerized Neuropsychological Test Battery (CNTB) modules, measuring attention/concentration, verbal and visual memory, and working memory, as well as two paper and pencil processing speed tests: Symbol Digit Modalities Test (SDMT) and verbal associative fluency test (FAS), the novel extended release Topiramate formulation (SRx-502) was shown to be associated with both significantly reduced cognitive impairment and fewer reduced adverse events.

Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's office -- jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package and access to the Spherics electronic data room.

About Spherics

Spherics has built a strong intellectual property position around its drug delivery technologies and products. The Company has a broad range of issued US and international patents that they have applied to their four central nervous system products. These patents cover polyanhydride-based bioadhesive polymers and nanotechnology (PIN(TM)). In addition to these issued patents, Spherics has filed numerous applications covering compositions of matters of its proprietary polymers (SPHEROMERS(TM)), novel oral delivery sy
'/>"/>

0

GOOD

Page: 1 2
Related medicine technology :

1. Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels
2. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
3. Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
4. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
5. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
6. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
7. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
8. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
9. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
10. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
11. CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial

Post Your Comments:

Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to ...( Findings Presented At The American S...),Health